20250403-招银国际-晶泰控股-P-02228.HK-AI-driven_innovation_unlocks_expansive_commercial_prospects_5页_1mb

XtalPi (2228 HK) Summary

Core Content

XtalPi (2228 HK) is a company leveraging AI-driven innovation to unlock commercial prospects across multiple sectors. The company's growth is primarily fueled by its intelligent robotics solutions and drug discovery services. In FY24, XtalPi reported a revenue increase of 52.8% YoY to RMB266mn, with the intelligent robotics segment growing by 87.8% YoY to RMB163mn. Revenue from drug discovery solutions also rose by 18.2% YoY to RMB104mn, supported by an expanded customer base and more revenue-generating programs.

Despite the growth in revenue, XtalPi continued to report adjusted net losses in FY24, with a 12.5% YoY reduction to RMB457mn. This is attributed to R&D expenses decreasing by 13.0% YoY to RMB418m, while SG&A expenses increased by 36% YoY to RMB489mn, mainly due to higher share-based compensation and listing-related costs. Contract fulfillment costs rose by 13.3% YoY to RMB143mn, in line with the expansion of service delivery.

As of the end of 2024, XtalPi had a RMB3.1bn cash balance, and further strengthened its financial position by completing two fundraising placements in early 2025, raising HK$3.2bn to boost cash reserves and support future growth initiatives.

Main Points

• AI-driven Innovation: XtalPi's proprietary AI platform powers growth in both drug discovery and intelligent robotics.
• Strategic Collaborations: The company has partnered with leading global and domestic pharmaceutical companies such as Eli Lilly, J&J, UCB, Zhuhai United Lab, Signet Therapeutics, META Biopharma, and N1 Life.
• Product Development: A drug candidate co-developed with Signet for diffuse gastric cancer entered Phase I clinical trials in China and the US, while another with META for primary hyperoxaluria progressed to the IND stage.
• Cross-Industry Partnerships: XtalPi has extended its reach into materials science, agriculture, consumer, AI infrastructure, and other emerging verticals, showcasing its scalable AI-enabled solutions.
• Financial Performance:
  • Revenue Growth: From RMB174mn in FY23A to RMB266mn in FY24A, with projected growth to RMB404mn in FY25E, RMB816mn in FY26E, and RMB1,184mn in FY27E.
  • Profitability: Continued net losses in FY24, but with adjusted net profit expected to turn positive in FY27E.
  • Cash Position: Strong cash reserves at RMB3.1bn as of end-2024, and HK$3.2bn raised in early 2025.
• Valuation & Target Price: Based on a DCF model, the target price is set at HK$7.57, with a 30.6% upside from the current price of HK$5.80.

Key Information

• Market Capitalization: HK$23,314.9mn
• Average 3-Month Turnover: HK$714.9mn
• 52-Week High/Low: HK$3.05 / HK$16.20
• Total Issued Shares: 4,019.8mn
• Shareholding Structure:
  • Tencent Holdings: 10.9%
  • QuantumPharm ROC: 7.4%
• Financial Highlights:
  • R&D Expenses: Reduced by 13.0% YoY to RMB418m
  • SG&A Expenses: Increased by 36% YoY to RMB489m
  • Net Profit: RMB-1,515mn in FY24, projected to turn positive in FY27E
  • Cash Flow: Net cash from operations was RMB-1,433mn in FY24, with expected positive cash flows in FY27E
• Growth Projections:
  • Revenue: Expected to grow significantly, with 51.5% YoY growth in FY25E and 102.2% YoY growth in FY26E.
  • FCFF (Free Cash Flow to Firm): Expected to increase from RMB-381mn in FY25E to RMB2,843mn in FY27E.
  • Terminal Value: Projected at RMB52,024mn in FY27E.
• DCF Valuation: Based on a WACC of 9.45% and a terminal growth rate of 4.0%, the DCF per share is estimated at HK$7.57.
• Risk Analysis:
  • Potential Delays in partnered R&D pipelines
  • Uncertainty in the sustainability of commercialization
  • Possible Sell-off following lock-up expiry
• Analyst Recommendation: Maintain BUY, indicating strong long-term value creation potential across multiple sectors.

Financial Summary (Key Figures)

Analyst Ratings

• BUY: Indicates potential return of over 15% over the next 12 months
• OUTPERFORM: Suggests the industry is expected to outperform the relevant market benchmark
• HOLD: Indicates potential return of +15% to -10%
• SELL: Indicates potential loss of over 10%

Disclosures

• The research analyst certifies that the views expressed reflect their personal opinions and are not influenced by compensation.
• No trading occurred in the stock covered in the report within 30 days prior to the report's release.
• The analyst will not trade in the stock for 3 business days after the report's release.
• The report may be subject to conflicts of interest, as CMBIGM has investment banking relationships with the companies mentioned.
• The report is not individually tailored and should be used for independent evaluation.

Conclusion

XtalPi is positioned for long-term value creation through AI-driven innovation and cross-industry applications. With strong cash reserves and strategic collaborations, the company is expected to see significant revenue growth and improved profitability in the coming years. Despite the current net losses, the target price suggests positive potential. However, the company faces risks such as R&D delays, commercialization uncertainty, and lock-up expiry. The BUY recommendation reflects the analyst's confidence in the company's growth prospects and commercialization potential.